Cycled Testosterone Replacement Study: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Cycled Testosterone Replacement Study (NCT00957528), a randomized phase 1 study. The primary outcome is Changes in Basal Muscle Protein Synthesis and Breakdown as Measured by Stable Isotope Metabolic Studies at Baseline and at Five Months.

2. Clinical Question

The study summary also identifies body composition, muscle metabolism, muscle strength, and bone metabolism as areas used to assess effectiveness. Those stated areas describe the study’s aims; they do not establish that any particular outcome changed. The available record supports a description of the trial question and design, but not a conclusion about comparative effects.

3. Trial Design

The registry record describes a phase 1, randomized, triple-masked, parallel study. It lists an enrollment of 26 and a completed status. The study began in 2006-01, with primary completion in 2008-12. The sponsor is The University of Texas Medical Branch, Galveston. The record does not explain how the randomization sequence was generated, how assignments were concealed, or which people were included among the three masked groups. Those details are not reported in the registry record.

Three parallel groups are described. The placebo group received weekly placebo treatment for five months. The continuous testosterone group received weekly testosterone treatment for five months. The monthly cycled testosterone group alternated a month of weekly testosterone treatment with a month of weekly placebo treatment over five months. This creates a direct contrast between continuous and intermittent dosing, while the placebo group provides a comparison for the treatment regimens.

The primary outcome is defined at baseline and five months, and its stated population is subjects who completed the entire treatment protocol. The enrollment figure should not be treated as the number who completed that protocol or as the denominator for each outcome: completion counts and the numbers analyzed for the primary outcome are not reported in the registry record. The outcome description does not specify whether the principal comparison was between all three groups, whether selected pairwise comparisons were planned, or how repeated measurements were handled.

Randomization can help balance measured and unmeasured participant characteristics across groups on average; it does not guarantee identical groups in a small trial. Masking can reduce the influence of expectations on care or measurement, but the record does not identify which roles were masked. The posted design information alone does not establish the analysis method, the extent of adherence, or whether all randomized participants contributed outcome data.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Screening was conducted at the ITS-CRC where the subject was consented and screening was conducted to identify eligible subjects.Screening included blood testing and a stress test to determine fitness for physical function testing. Subjects were excluded due to elevated PSA levels, testosterone levels above entry criteria or occult disease.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Subjects who completed the entire treatment protocol

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Changes in Basal Muscle Protein Synthesis and Breakdown as Measured by Stable Isotope Metabolic Studies at Baseline and at Five Months, measured over 5 Months.

The primary outcome is titled as changes in basal muscle protein synthesis and breakdown measured by stable isotope metabolic studies at baseline and five months. The stated unit is percent per hour, and the outcome type is a mean with standard deviation. Its listed population is subjects who completed the entire treatment protocol.

The description explains measurement of fractional synthetic rate (FSR) for mixed muscle. It uses incorporation of labeled L-phenylalanine into protein and a precursor-product model based on enrichment in two muscle biopsies, the interval between biopsies, and enrichment in the muscle intracellular pool. In general, a stable-isotope approach tracks labeled molecules through a biological process, allowing a rate of protein synthesis to be estimated rather than relying only on a single concentration measurement. FSR expresses the measured synthesis rate relative to the relevant protein pool over time.

Muscle protein synthesis is one component of muscle protein turnover; protein breakdown is a distinct process. Although the outcome title names both synthesis and breakdown, the registry description specifies the FSR calculation for synthesis. The measurement method and numerical results for breakdown are not reported in the registry record. Nor does the record state how a change was calculated or how the two components were combined, if at all. The endpoint is relevant to the study’s muscle-metabolism question, but a laboratory measure of protein turnover is not itself a direct measure of muscle strength or physical function.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record supplies design and outcome descriptions but does not report a detailed statistical analysis plan or a numerical analysis of the primary outcome. The explanations below are general statistical context; they should not be read as claims about methods used in this trial.

What does randomization contribute?

In general, random assignment aims to make treatment groups comparable at the start of a study, including with respect to characteristics that were not measured. It supports a causal comparison when the assigned groups are analyzed appropriately and outcome follow-up is sufficiently complete. Randomization does not guarantee exact balance, particularly in a small study. The record says the study was randomized, but the sequence-generation procedure, allocation concealment, and analysis according to assigned group are not reported in the registry record.

What does the parallel design mean?

In a parallel design, participants are assigned to a group and receive that group’s regimen during the study, rather than each participant receiving every regimen in sequence. Here the record describes placebo, continuous testosterone, and monthly cycled testosterone groups, with treatment schedules lasting five months. In general, a parallel-group comparison estimates differences between groups at a selected outcome time or in change over time. The registry record does not state the exact primary contrast or the model used to compare the groups.

How should the mean and standard deviation be understood?

The primary outcome is identified as a mean of a continuous measure, with standard deviation as the dispersion measure. In general, the mean is the arithmetic average of observed values. The standard deviation describes how dispersed individual values are around their group mean; it is not the uncertainty in the estimated mean. Uncertainty about a mean or a between-group contrast is usually described using a standard error or confidence interval, which depends on the sample size and analysis method. No primary-outcome group means, standard deviations, or uncertainty intervals are reported in the registry record.

What does a change from baseline represent?

Comparing follow-up with baseline can describe within-person change, while comparing those changes between groups can estimate whether average change differs across regimens. These are not interchangeable questions: a change within one group does not by itself show that the group changed differently from another group. In general, an analysis may model follow-up values while accounting for baseline, compare change scores, or use a repeated-measures model. The registry record does not state which approach was used, how baseline values were incorporated, or how measurements at different times were handled.

How does the isotope measurement relate to the endpoint?

The record describes FSR as a continuous rate measured through labeled phenylalanine incorporation into mixed muscle protein, using enrichment information from muscle biopsies and an intracellular precursor pool. In general, a stable-isotope method estimates a biological process by tracing the movement of a labeled substance over time. The resulting measure depends on the stated model and measurement conditions. The registry description gives the calculation concept for synthesis, but not numerical estimates, measurement variability, or a corresponding operational description for protein breakdown. Thus, the formula explains what the synthesis measure is intended to represent; it does not provide a treatment effect.

What can a confidence interval or p-value tell a reader?

In general, a confidence interval gives an interval estimate of an effect and communicates its statistical precision under the assumptions of the method. A narrow interval indicates greater precision than a wide interval, but precision is not the same as clinical importance. A p-value describes how compatible the observed data are with a specified null model, given the assumptions used. It does not give the probability that a treatment is effective, and it does not measure the size of an effect. The registry record does not report a confidence interval or p-value for the primary comparison, so neither statistical precision nor evidence against a null hypothesis can be assessed from the record.

Why do distributional assumptions matter?

In general, statistical models make assumptions about how outcomes vary and how observations relate to each other. For continuous outcomes, an analysis may rely on assumptions about residuals or use methods that are less dependent on a particular distribution. For count outcomes, over-dispersion matters when variation exceeds what a chosen count model expects; ignoring it can make uncertainty appear too small. These are general considerations, not descriptions of analyses used in this study. The registry record does not report model diagnostics, transformations, robust methods, or an analysis of adverse-event counts.

How should planning calculations be read?

The record describes sample-size planning illustrations using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It says the effect to detect is framed as a stated fraction of the observed effect; for time-to-event outcomes, the planning convention uses a total event count, while other outcomes use participants per arm. These are prospective planning calculations, not observed power and not evidence that a study achieved a particular probability of detecting an effect. Planning calculations depend on assumptions about the effect and variability. The numerical observed primary effect and its variability are not reported in the registry record, so the assumptions should not be mistaken for a result of this trial.

10. Multiplicity, Missing Data and Analysis Populations

The primary outcome title refers to changes in muscle protein synthesis and breakdown, and the registry record indicates that the primary outcome has several categories or time points and was not reduced to one comparison. The record also lists secondary outcomes concerning bone mineral density, bone-turnover markers, and inflammatory biomarkers. It reports six outcome measures and zero analyses. These registry entries show that outcome definitions are present without a corresponding set of reported analyses in the record.

When a study evaluates multiple outcomes, time points, or group contrasts, the chance of obtaining at least one apparently unusual result can increase. In general, multiplicity procedures may define a primary comparison, adjust significance thresholds, or prioritize outcomes in a prespecified sequence. The appropriate approach depends on the study question and analysis plan. The statistical plan, the intended primary contrast, and any multiplicity adjustment are not reported in the registry record. It is therefore not possible to determine whether any hypothetical comparisons were treated as confirmatory or exploratory.

The primary outcome population is described as subjects who completed the entire treatment protocol. The number who completed treatment, group-specific analysis counts, reasons for noncompletion, and missing-data handling are not reported in the registry record. The record also does not state whether all randomized participants were analyzed according to their assigned group, whether participants with incomplete measurements were excluded, or whether any method was used to account for missing values.

These omissions matter because complete-case results may differ from results that include all randomized participants, particularly if missingness is related to treatment or outcome. In general, an analysis population should be identified clearly, and the assumptions behind missing-data methods should be stated. Here, the completion-based outcome population is named, but the flow from enrollment to that population and the analytical procedures are not reported. No conclusion about attrition, bias from missing data, or multiplicity control can be drawn from the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The registry record lists serious adverse events and other adverse events separately for the three groups. Serious adverse events are recorded as zero among 8 at risk in the placebo group, zero among 8 at risk in the monthly cycled testosterone group, and zero among 8 at risk in the continuous testosterone group. Other adverse events are recorded as one among 8 at risk in the placebo group, zero among 8 at risk in the monthly cycled testosterone group, and one among 8 at risk in the continuous testosterone group. Death counts are not reported in the registry record, and no serious adverse event terms are listed.

These entries are counts, not estimates of comparative risk. In general, an adverse-event count does not by itself establish whether an event was caused by treatment, and a zero count does not establish that an event cannot occur. The record does not provide event descriptions for the other adverse events, severity details beyond the serious-versus-other categories, exposure-adjusted rates, or a statistical comparison. The listed at-risk numbers apply to these safety entries; they should not be treated as the primary-outcome analysis counts. Given the limited safety information, the registry entries support only a description of the recorded counts, not a conclusion about relative safety.

12. What the Result Does, and Does Not, Mean

The registry record establishes that investigators planned a randomized comparison of placebo, continuous testosterone, and monthly cycled testosterone in older men. It identifies a five-month primary outcome concerning basal muscle protein synthesis and breakdown and describes a stable-isotope method for measuring fractional synthetic rate. Those details clarify the scientific question and what the synthesis measure is intended to capture.

The record does not report a numerical primary-outcome result or a reduced group comparison. It therefore does not establish whether the groups differed, in which direction any difference went, or how large or precise a difference might have been. The enrollment figure is not a substitute for outcome data, and the primary outcome’s completer-based population does not reveal how many participants were analyzed. No inferential conclusion about efficacy follows from the design description alone.

In general, a biomarker or metabolic rate can inform understanding of a physiological process, but it is not automatically equivalent to a change in muscle strength, physical function, or another clinical outcome. The study summary mentions body composition, muscle metabolism, muscle strength, and bone metabolism as areas of interest. The registry record does not provide results that establish changes in those areas. Likewise, the listed secondary outcome topics do not constitute evidence of an effect.

The safety entries report no serious adverse events in the listed at-risk groups and small counts of other adverse events. They are descriptive entries, not proof that a regimen is free of risk or that the groups have equivalent safety. The record does not report deaths or an inferential safety comparison. Overall, the information supports understanding the trial’s design, measurement, and limited recorded safety counts, while leaving the primary treatment comparison unresolved in the registry record.

13. Why This Trial Matters Statistically

This trial is statistically interesting because it distinguishes a cyclic dosing schedule from continuous dosing and placebo within a randomized, parallel design. The schedules are clearly described, and the primary outcome targets muscle protein metabolism rather than relying only on a broad clinical label. The use of a stable-isotope method gives the endpoint a mechanistic focus: it is intended to quantify a rate of protein synthesis in mixed muscle.

The record also illustrates why an outcome definition and an outcome result are different things. A title, measurement method, and time frame can make a study question understandable, but they cannot show the estimated effect or its uncertainty. Here, the primary outcome has several categories or time points and is not reduced to one comparison; the record lists six outcome measures and zero analyses. Without numerical results and a defined contrast, readers cannot assess the primary comparison statistically.

The completer-based outcome population is another important design detail. In general, restricting an analysis to participants who complete treatment can affect comparability if completion is related to assigned regimen or outcome. The record does not report completion counts or missing-data methods, so the consequences cannot be assessed. This is a reminder that enrollment, completion, and analysis populations are different concepts and should be reported separately.

Finally, the record’s planning convention should be distinguished from evidence observed in the trial. Planning calculations based on an observed effect and specified assumptions do not become observed power and cannot replace a reported effect estimate. The available information therefore highlights the value of transparent reporting: prespecified comparisons, analysis populations, missing-data handling, estimates, and uncertainty are needed to move from a plausible design to an interpretable statistical result.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpretation is the absence of a numerical primary-outcome analysis in the registry record. Although the primary measure, unit, time frame, and completer population are described, the record does not give group summaries or a comparison that would quantify the effect. Its note that the outcome has several categories or time points and is not reduced to one comparison further prevents a single primary estimate from being identified.

The distinction between the outcome title and its measurement description also matters. The title includes both synthesis and breakdown, while the description specifies the FSR calculation for synthesis. The method for breakdown and numerical results for either component are not reported in the registry record. The record does not explain whether the components were separate outcomes, how a change was defined, or how repeated observations were analyzed.

The primary outcome is defined for subjects who completed the full treatment protocol, but the number of completers and the path from enrollment to analysis are not reported. There is no account of missing measurements, treatment adherence, withdrawals, or reasons for noncompletion. The record does not specify whether the analysis followed randomized assignment, how protocol deviations were handled, or whether any sensitivity analyses were conducted.

Other limitations arise from the absent statistical plan. The randomization method, allocation concealment, masking roles, primary contrast, model, multiplicity strategy, and handling of baseline values are not reported in the registry record. The enrollment figure alone does not provide evidence about the precision of the primary estimate, particularly because the analyzed population and outcome variability are not reported. These omissions limit statistical assessment; they do not establish that the trial was conducted improperly.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Cycled Testosterone Replacement Study — NCT00957528.
• Registry record last updated 2012-09-10; status last verified 2012-09.
• Results first posted 2012-08-21.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed, phase 1, randomized, triple-masked, parallel study sponsored by The University of Texas Medical Branch, Galveston. Enrollment was 26. The study summary concerns men aged 60 to 85 years and compares weekly placebo, weekly testosterone, and a regimen alternating a month of weekly testosterone with a month of weekly placebo over five months.

The primary outcome concerns changes in basal muscle protein synthesis and breakdown from baseline to five months. Its description specifies a stable-isotope FSR measure for mixed muscle, and its stated population is subjects who completed the entire treatment protocol. The record lists six outcome measures and zero analyses; it does not provide a reduced numerical primary comparison. Safety entries list zero serious adverse events in each group and other adverse event counts of one, zero, and one. Death counts are not reported. The available record describes the study question and selected safety counts, but does not support a statistical conclusion about the primary treatment effect.